NCT01451645View on ClinicalTrials.gov

Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2012

Conditions

Intercritical Gout

Interventions

DRUG

Colchicine (Colcrys®)

daily 0.6 mg colchicine dosing for 16 weeks

DRUG

placebo

daily placebo dosing for 16 weeks

DRUG

allopurinol

background therapy

Trial Locations (37)

Unknown

Alabaster

Mesa

Upland

Trumbull

DeBary

Jacksonville

Kissimmee

Canton

Boise

Lexington

Bethesda

Reisterstown

Bingham Farms

Brooklyn Center

Kansas City

Billings

Elizabeth

Albuquerque

New York

Charlotte

Hickory

Morganton

Winston-Salem

Duncansville

Reading

West Reading

Greer

Mt. Pleasant

Johnson City

Dallas

Katy

San Antonio

Salt Lake City

West Jordan

Norfolk

Seattle

Wauwatosa

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01451645 - Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol | Biotech Hunter | Biotech Hunter